Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690561 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL1690560 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL26017597 | 0.90 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26251626 | 0.86 | — | — | |
| SCHEMBL16465017 | 0.86 | — | — | |
| SCHEMBL16464078 | 0.86 | SLC6A2 (0.53) | SLC6A2DRD2DRD3 | |
| SCHEMBL18433828 | 0.86 | DRD2 (0.52) | DRD2DRD3 | |
| SCHEMBL16464076 | 0.86 | SLC6A2 (0.53) | SLC6A2DRD2DRD3 | |
| SCHEMBL1692968 | 0.85 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL28056326 | 0.84 | DRD2 (0.58) | SLC6A2SLC6A4SLC6A3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841282-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841282-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130338119-A1 | Pyrrolidinone Benzenesulfonamide Derivatives as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231655-B1 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMA (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7994166-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994166-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2231655-A2 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATI VES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009064747-A2 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATI VES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | SLC6A2 460/4885SLC6A4 351/4885SLC6A3 417/4885 |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | TRPV1, TRPV5, TRPA1 | SLC6A2 1294/4885SLC6A4 806/4885SLC6A3 859/4885 |
| US-20130338119-A1 | Pyrrolidinone Benzenesulfonamide Derivatives as Modulators of Ion Channels | KCNJ2, KCNN2, KCNJ1 | SLC6A2 994/4885SLC6A4 629/4885SLC6A3 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.